The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
29-Aug-02
$6.2 billion
Target:
Marconi plc
Advised the official committee of bondholders of Marconi, a leading telecom equipment provider, on the financial restructuring of Marconi's £4 billion of externally held financial indebtedness
15-Dec-17
$6.0 billion
Target:
Avaya
Advised The Bank of New York Mellon in its role as the Indenture Trustee to selected First Lien Notes throughout Avaya’s Chapter 11 proceedings
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
10-Sep-20
$2.1 billion
Target:
Skillsoft Limited
Acquiror:
N/A
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Skillsoft Limited, a leading provider of e-learning and performance support solutions globally
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
11-Dec-12
$862 million
Target:
TNS, Inc.
Acquiror:
Siris Capital Group
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
03-Feb-20
$650 million
Target:
Clover Wireless
Acquiror:
First Lien Term Loan B Lenders
Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation
13-Dec-11
$345 million
Target:
Cabot Microelectronics Corporation
Advised Cabot Microelectronics Corporation on its new capital management initiative, including a leveraged recapitalization via a special dividend
25-Jan-17
$325 million
Target:
Ad Hoc Group of Senior Secured Noteholders
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
18-Jan-22
$321 million
Target:
Fusion Connect, Inc.
Acquiror:
N/A
Advised Fusion Connect, Inc., a leading service provider of cloud communications and secure network solutions with a focus on serving mid-market and enterprise businesses on its comprehensive balance sheet recapitalization
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
29-Nov-18
$86 million
Target:
Wave Computing
Advised Wave Computing, a leading artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on its successful $86mm Series E financing
01-May-09
$65 million
Target:
euNetworks Group Limited
Advised euNetworks Group Ltd, a Singapore listed operator of a fibre telecommunications network in Europe, on a repurchase at a discount of the majority of its outstanding convertible bonds, financed by a placement and rights issue
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
23-Mar-09
$NA
Target:
BearingPoint, Inc.
Acquiror:
Various
Advised BearingPoint, Inc. on the sale of substantially all of its assets, pursuant to a Section 363 process
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise